Pyxis Oncology Announces New Clinical Data for MICVO ADC Targeting Solid Tumors to Be Presented at ESMO 2025 and AACR-NCI-EORTC
Reuters
Oct 14
<a href="https://laohu8.com/S/PYXS">Pyxis Oncology</a> Announces New Clinical Data for MICVO ADC Targeting Solid Tumors to Be Presented at ESMO 2025 and AACR-NCI-EORTC
Pyxis Oncology Inc. has announced the upcoming presentation of translational data for micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate $(ADC)$, at two major medical meetings. The data will be shared in two posters at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, and in six posters at the AACR-NCI-EORTC International Conference in Boston, Massachusetts. MICVO is designed to target extradomain-B of fibronectin (EDB+FN) and employs an extracellular-cleaving mechanism. The findings to be presented include MICVO's mechanism of action, which involves direct tumor cell killing, bystander effect, and immunogenic cell death, as well as its effects on tumor microenvironment remodeling and immune activation. Presentation materials will be made available on the company's website following the conclusion of each meeting.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9544670-en) on October 13, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.